Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

21.03
+0.17000.81%
Pre-market: 20.50-0.5300-2.52%05:27 EDT
Volume:2.66M
Turnover:55.56M
Market Cap:2.22B
PE:-15.98
High:21.16
Open:20.56
Low:20.18
Close:20.86
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.78
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.45
PE(LYR):-2.95

Loading ...

Sarepta Therapeutics Inc : Wedbush Raises Target Price to $35 From $29

THOMSON REUTERS
·
Mar 26

Bernstein Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 26

Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating

TIPRANKS
·
Mar 26

Sarepta price target raised to $13 from $9 at Citi

TIPRANKS
·
Mar 26

U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop

Reuters
·
Mar 26

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 26

Sarepta Therapeutics Inc : Piper Sandler Raises Target Price to $23 From $16

THOMSON REUTERS
·
Mar 26

ETF Daily | SRPU Soars 69%; FLYT Surges 37%; ARMG Jumps 33%; Space and Semiconductor Themes Lead

ETF Tracker
·
Mar 26

Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today

Benzinga_recent_news
·
Mar 26

U.S. Small Caps Rise; Sarepta Therapeutics Climbs Highest

Dow Jones
·
Mar 26

Sarepta price target raised to $25 from $20 at Morgan Stanley

TIPRANKS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Sarepta Therapeutics Up Over 30%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Dow Jones
·
Mar 26

These Stocks Are Today's Movers: Arm, Intel, Firefly Aerospace, Robinhood, Sarepta, JD.com, and More -- Barrons.com

Dow Jones
·
Mar 26

Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. -- Barrons.com

Dow Jones
·
Mar 26

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

TIPRANKS
·
Mar 25

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

TIPRANKS
·
Mar 25

Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases

MT Newswires Live
·
Mar 25

Shares of Sarepta Therapeutics up 3.2% Premarket After Muscle Disease Drugs Show Promise in Early-to-Mid Stage Trials

THOMSON REUTERS
·
Mar 25

BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1

Reuters
·
Mar 25